news and events

Wolfram Goessling welcomed as new HST Director

Friday, August 19, 2016


In an announcement to the Harvard Medical School and Harvard-MIT Health Sciences and Technology communities on Wednesday, August 17, 2016, the news was shared that Dr. Wolfram Goessling is the new HMS director of the HST program. Dr. David Golan, Dean for Basic Science and Graduate Education, and Dr. Edward Hundert, Dean for Medical Education, said the following:

Please join us in welcoming Wolfram Goessling, MD, PhD, as the new HMS director of the Harvard-MIT Health Sciences and Technology program and the new advisory dean and director of the Irving M. London Society.

Goessling succeeds David Cohen, MD, PhD, to whom we owe our deepest gratitude for his visionary leadership during his nearly decade-long tenure at the helm of HST. Goessling is assuming this position today.  

Goessling is a brilliant physician-scientist with a robust and innovative research program. He also is an outstanding and sought-after clinician, a world-class mentor of both medical and graduate students, and an award-winning educator who has taught in the HST program since 2003.   
Board certified in oncology and gastroenterology, Goessling’s clinical work focuses on gastrointestinal malignancies, and his research aims to unravel basic mechanisms of liver development, regeneration and cancer. Findings from his laboratory are already being translated into potential therapies at the Dana-Farber Cancer Institute. 
Goessling obtained both his medical degree and doctorate in physiology from the Witten/Herdecke University Medical School in Germany.  He trained in internal medicine at Brigham and Women’s Hospital, serving as chief resident, and completed clinical and research fellowships in both gastroenterology and hematology-oncology at Massachusetts General Hospital, Dana-Farber and Boston Children’s Hospital. 
Goessling is an associate professor of medicine at HMS, an associate physician in the Divisions of Genetics, Gastroenterology and Medical Oncology at Brigham and Women’s, and a practicing medical oncologist at Dana-Farber, where he treats patients with hepatobiliary cancers.  
We look forward to supporting Goessling as he joins with HST faculty and students across the HMS and MIT campuses to further invigorate this trailblazing program that, over the past four decades, has trained more than 1,000 physicians and scientists. We are certain that under his leadership, HST will continue to spark innovations and transform biomedical science, medical technology and the delivery of world-class patient care. 
Please join us in welcoming Wolfram to this important leadership role.   
David and Ed